(+/-)-6-Fluoro-Epinephrine | 115562-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (+/-)-6-Fluoro-Epinephrine
• 英文别名: 4-Fluoro-5-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
• CAS: 115562-29-3
• 化学式: C₉H₁₂FNO₃
• 分子量: 201.198
• InChiKey: DKBXREAGJFVVAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-[2-Fluoro-4,5-bis(phenylmethoxy)phenyl]-2-(methylamino)ethanol 在 palladium on activated charcoal 氢气 作用下， 生成 (+/-)-6-Fluoro-Epinephrine
  参考文献：
  名称：

  Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them

  摘要：

  (R)-6F-苯肾上腺素，基本上不含(S)-6F-苯肾上腺素，并且包括(R)-6F-肾上腺素或(R)-6F-苯肾上腺素的麻醉制剂，其相比含有它们非氟化类似物的制剂具有改善的稳定性，已被披露。此外，还披露了通过给予哺乳动物麻醉制剂来提供血管收缩的方法。麻醉组合物可以包括麻醉剂、具有结构的(R)-手性化合物：其中R1、R2和R4独立地选择自—H或—F，R1、R2和R4中至少一个是—F，R3选择自—OH、—H或—F，或其药用可接受的盐或酯，所述血管收缩剂基本上不含(S)-手性形式。此外，还披露了一种利用杏仁羟基亚硝基酰酶酶将氰化物立体加到环氟化苯甲醛的方法，采用可逆溶解聚合物共轭形式提供(R)-Finezyme™-H系列生物催化剂。还披露了几种这样的生物催化剂。

  公开号：

  US20040002549A1

文献信息

• [EN] METHODS, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY AND MOOD DISORDERS<br/>[FR] PROCÉDÉS, COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITERMENT DE L'ANXIÉTÉ ET DES TROUBLES DE L'HUMEUR
  申请人：UNIV NEW YORK

  公开号：WO2011133212A1

  公开（公告）日：2011-10-27

  Compounds and pharmaceutical compositions containing such compounds having formula (I) are provided: where R1, R2a, R2b, R3, R4, and R5 are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including anxiety and mood disorders such as depression.
• Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
  申请人：——

  公开号：US20040002549A1

  公开（公告）日：2004-01-01

  (R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: 1 wherein R 1 , R 2 , and R 4 are independently selected from —H or —F, at least one of R 1 , R 2 , and R 4 is —F, and R 3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed. Several such biocatalysts are disclosed.

  (R)-6F-苯肾上腺素，基本上不含(S)-6F-苯肾上腺素，并且包括(R)-6F-肾上腺素或(R)-6F-苯肾上腺素的麻醉制剂，其相比含有它们非氟化类似物的制剂具有改善的稳定性，已被披露。此外，还披露了通过给予哺乳动物麻醉制剂来提供血管收缩的方法。麻醉组合物可以包括麻醉剂、具有结构的(R)-手性化合物：其中R1、R2和R4独立地选择自—H或—F，R1、R2和R4中至少一个是—F，R3选择自—OH、—H或—F，或其药用可接受的盐或酯，所述血管收缩剂基本上不含(S)-手性形式。此外，还披露了一种利用杏仁羟基亚硝基酰酶酶将氰化物立体加到环氟化苯甲醛的方法，采用可逆溶解聚合物共轭形式提供(R)-Finezyme™-H系列生物催化剂。还披露了几种这样的生物催化剂。